BIO-key Seeks Shareholder Approval for 53% Dilutive Warrant Exercise
BKYI is trading near its 52-week low of $2.9 (0.7% above the low).
Summary
BIO-key filed a definitive proxy supplement seeking shareholder approval for a warrant inducement transaction that could dilute existing holders by 53.2% if the new warrants are fully exercised. The vote is set for September 3, 2026.
Key Events · Financing and Capital Events · BKYI
-
Warrant Inducement Transaction
On August 10, 2026, BIO-key induced Armistice Capital to exercise 618,334 existing warrants at a reduced price of $4.06 per share, generating approximately $2.51 million in gross proceeds. In exchange, the company issued new warrants for 1,236,668 shares (200% coverage) at the same $4.06 exercise price.
-
53.2% Potential Dilution
If the new warrants are fully exercised, 1,236,668 additional shares would be issued, diluting existing shareholders by approximately 53.2% based on 1,087,360 shares outstanding at the July 15, 2026 record date. The new warrants carry a 4.99% beneficial ownership limitation.
-
Shareholder Vote Required
Nasdaq Listing Rule 5635(d) requires shareholder approval because the issuance exceeds 20% of outstanding shares at a price below the Minimum Price. The vote is scheduled for the Annual Meeting on September 3, 2026, at 10:00 a.m. local time in Holmdel, NJ.
-
Additional Financing Potential
Full exercise of the new warrants would generate an additional $5,020,872 in gross proceeds. If shareholders reject the proposal, the new warrants cannot be exercised, eliminating this potential source of future equity financing.
Analysis · BKYI · Technology
BIO-key is asking shareholders to approve the issuance of up to 1,236,668 shares upon exercise of new warrants issued in its August 10, 2026 warrant inducement transaction with Armistice Capital. If approved and fully exercised, this would dilute existing shareholders by approximately 53.2% based on the 1,087,360 shares outstanding at the record date. The company already received $2.51 million from the exercise of existing warrants at a reduced price of $4.06 per share, and the new warrants could generate an additional $5.02 million in gross proceeds. This comes as BIO-key trades near its 52-week low of $2.90, well below the $4.06 exercise price, and follows a series of distress signals including a going concern warning, Nasdaq delisting notices, and an auditor change. The vote is scheduled for September 3, 2026, and approval is required under Nasdaq Listing Rule 5635(d) because the issuance exceeds 20% of outstanding shares at a price below the Minimum Price.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BKYI was trading at $2.92 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $2.90 to $19.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.